ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

Other Contract Concepts Approved By DCE Board

March 10, 1989

Capitol Hill: Senators Reintroduce Breast Cancer Stamp.

January 28, 2005

NCI’s Douglas Lowy and John Schiller Honored with National Medal

December 12, 2014

DCE Board Sets Aside $2 Million For Radiation Grants Program; Okays Concept For Add-On To ASCUS Trial

October 13, 1995

ICF Clement Joins Dynalectron In FCRF

January 9, 1987

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011